WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998001149) VARIANTS OF HUMAN CILIARY NEUROTROPHIC FACTOR (hCNTF) WITH A RANGE OF ACTION DIFFERENT FROM THAT OF THE WILD-TYPE MOLECULE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/001149    International Application No.:    PCT/IT1997/000163
Publication Date: 15.01.1998 International Filing Date: 10.07.1997
Chapter 2 Demand Filed:    05.02.1998    
IPC:
A61K 38/00 (2006.01), C07K 14/475 (2006.01)
Applicants: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. [IT/IT]; Via Pontina Km. 30.600, I-00040 Pomezia (IT) (For All Designated States Except US).
LAUFER, Ralph [IT/IT]; (IT) (For US Only).
DI MARCO, Annalise [IT/IT]; (IT) (For US Only)
Inventors: LAUFER, Ralph; (IT).
DI MARCO, Annalise; (IT)
Agent: DI CERBO, Mario; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT)
Priority Data:
RM96A000492 10.07.1996 IT
Title (EN) VARIANTS OF HUMAN CILIARY NEUROTROPHIC FACTOR (hCNTF) WITH A RANGE OF ACTION DIFFERENT FROM THAT OF THE WILD-TYPE MOLECULE
(FR) VARIANTS DE FACTEUR NEUROTROPHIQUE CILIAIRE HUMAIN (hCNTF) AYANT UN CHAMP D'ACTION DIFFERENT DE CELUI DE LA MOLECULE DE TYPE SAUVAGE
Abstract: front page image
(EN)The variants of human ciliary neurotrophic factor (hCNTF) according to the present invention are characterised by substitution of phenylalanine 152 and/or of lysine 155 with alanine. These variants have biological properties that render them important as the active principles of drugs for the treatment of diseases and pathologies involving the nervous system or other pathologies involving cells responding to the CNTF. Figure 2 shows the results of stimulation of haptoglobin secretion from HepG2 cells by CNTF and the variants described in the invention.
(FR)Variants de facteur neurotrophique ciliaire humain caractérisés par la substitution de phénylalanine 152 et/ou de lysine 155 par alanine. Ces variants possèdent des propriétés biologiques qui les rendent importants en tant que principaux principes actifs de médicaments pour le traitement de maladies et de pathologies touchant le système nerveux ou d'autres pathologies touchant la réponse des cellules au CNTF. La figure 2 montre les résultats de la stimulation de la sécrétion d'haptoglobine de cellules HepG2 par le CNTF et les variants décrits dans la présente invention.
Designated States: AU, CA, CN, IL, JP, KR, MX, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)